Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectivelyEnded 2024 with ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

Overall, we were pleased with the efficacy signal observed in the trial ... its drug encorafenib in first-line mCRC patients, with a BRAF mutation. And to be clear, this is a totally separate ...

BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company ...

Filled with the top stories to start your day, and emergency news alerts.

The Signal is produced by senior students at the University of King’s College School of Journalism, Writing & Publishing.